BNP Paribas (ENXTPA:BNP): Exploring Valuation After Subtle Share Price Strength

BNP Paribas (ENXTPA:BNP) has been quietly drawing investor attention recently, not due to headline-grabbing news but rather some curious price action that could make you wonder if there is more beneath the surface. Sometimes, these subtler moves spark bigger questions. Is this a blip, or the early sign of a larger shift for France’s largest bank?

Over the past year, BNP Paribas’s share price is up roughly 30%, quickly outpacing most of its European peers. While the past month has seen the momentum soften, longer-term gains remain substantial, with a nearly 85% return over three years and close to 187% over five years. With annual growth in both revenue and net income, the bank’s recent performance has kept people guessing about its underlying value and the sustainability of this track record.

So as the shares catch their breath after an impressive year, the key question remains. Is there still a meaningful upside for new buyers, or is the market already looking ahead to the next phase of growth?

Most Popular Narrative: 16.7% Undervalued

According to the most widely followed narrative, BNP Paribas’s shares are trading at a meaningful discount to the estimated fair value. Analysts consider the bank undervalued relative to current and future performance expectations.

The integration of AXA IM and HSBC WM Germany, alongside ongoing expansion in high-growth markets (notably Turkey and Poland), is set to significantly broaden BNP Paribas's distribution network and wealth management capabilities. This will directly increase fee-based revenue and support long-term earnings growth through enhanced client acquisition and cross-selling opportunities.

Curious why this stock is trading well below the narrative’s fair value? It’s not just about international deals or market share. Behind the projection are some bold assumptions—ranging from revenue gains and profit jumps to future multiples that exceed the banking average. Want the full breakdown behind this headline number? The real reason for this “undervalued” label will surprise critical observers of BNP Paribas’s growth plans.

Result: Fair Value of €92.08 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent margin pressure in low-growth Eurozone markets or digital rivals outpacing BNP Paribas could quickly reshape the current bullish outlook.

Find out about the key risks to this BNP Paribas narrative.

Another Perspective: The SWS DCF Model

Another widely used approach, the SWS DCF model, tells a similar story and suggests that BNP Paribas could still be trading below its intrinsic worth. However, does this method overlook risks that multiples might catch, or is it revealing hidden long-term value?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out BNP Paribas for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own BNP Paribas Narrative

If these conclusions do not quite fit your perspective or you would rather dive deeper into your own analysis, you can shape your own view of BNP Paribas in just a few minutes by using Do it your way.

A great starting point for your BNP Paribas research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors know a single stock is just the beginning. Unlock new opportunities and boost your portfolio by using our screeners to find standouts in today’s rapidly changing market. Don’t let the next big winner pass you by. Seize your edge now with these powerful tools:

• Zero in on tomorrow’s tech disruptors shaking up medicine by using healthcare AI stocks to spot healthcare companies leveraging artificial intelligence for medical breakthroughs.
• Secure your future income by checking out dividend stocks with yields > 3% to uncover companies delivering consistent dividend yields above 3%.
• Catch early-stage companies with massive upside by tapping into penny stocks with strong financials and see which penny stocks are backed by robust financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com